Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 4 | 2021 | 303 | 1.300 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2025 | 47 | 1.010 |
Why?
|
| Immunoconjugates | 1 | 2023 | 46 | 0.790 |
Why?
|
| Telomere Shortening | 1 | 2019 | 34 | 0.600 |
Why?
|
| Telomerase | 1 | 2019 | 168 | 0.570 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 137 | 0.550 |
Why?
|
| Neutropenia | 1 | 2019 | 205 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1340 | 0.480 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1822 | 0.400 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2024 | 241 | 0.340 |
Why?
|
| Radiation Pneumonitis | 2 | 2022 | 10 | 0.330 |
Why?
|
| Cancer Survivors | 2 | 2022 | 247 | 0.270 |
Why?
|
| Adolescent | 11 | 2025 | 20542 | 0.250 |
Why?
|
| Mutation | 1 | 2019 | 6226 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 178 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2025 | 605 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 141 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 309 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 1 | 2025 | 396 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 153 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 357 | 0.180 |
Why?
|
| Child | 10 | 2025 | 25763 | 0.180 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 141 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 224 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1305 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 148 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 149 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 215 | 0.150 |
Why?
|
| Survivors | 1 | 2020 | 355 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 56 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 149 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 515 | 0.130 |
Why?
|
| Lung | 2 | 2022 | 1556 | 0.130 |
Why?
|
| Recurrence | 3 | 2025 | 1454 | 0.120 |
Why?
|
| Adult | 5 | 2025 | 31571 | 0.120 |
Why?
|
| Incidence | 2 | 2020 | 3375 | 0.110 |
Why?
|
| Humans | 14 | 2025 | 132064 | 0.110 |
Why?
|
| Stroke | 1 | 2022 | 1081 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 3089 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5412 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 222 | 0.090 |
Why?
|
| Female | 8 | 2025 | 70664 | 0.090 |
Why?
|
| Young Adult | 5 | 2025 | 9952 | 0.090 |
Why?
|
| Male | 8 | 2025 | 64938 | 0.080 |
Why?
|
| Radiotherapy Dosage | 2 | 2022 | 237 | 0.080 |
Why?
|
| Child, Preschool | 5 | 2025 | 14734 | 0.080 |
Why?
|
| Prognosis | 1 | 2019 | 5010 | 0.080 |
Why?
|
| Risk Factors | 2 | 2020 | 10938 | 0.070 |
Why?
|
| Neoplasms | 2 | 2022 | 2952 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1957 | 0.070 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 36 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2025 | 13000 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 33 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 81 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 98 | 0.050 |
Why?
|
| Infant | 3 | 2024 | 13048 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 200 | 0.050 |
Why?
|
| Organs at Risk | 1 | 2022 | 42 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 212 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 181 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 199 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 279 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 283 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 539 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 673 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 220 | 0.040 |
Why?
|
| Bleomycin | 1 | 2018 | 113 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 852 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 167 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 956 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1668 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1457 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1099 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17389 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1650 | 0.030 |
Why?
|
| Middle Aged | 2 | 2024 | 28993 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2164 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21426 | 0.010 |
Why?
|